Nonsmall cell lung carcinoma: Diagnostic difficulties in small biopsies and cytological specimens

Lukas Bubendorf; Sylvie Lantuejoul; Adrianus J. de Langen; Erik Thunnissen

doi:10.1183/16000617.0007-2017

Nonsmall cell lung carcinoma: Diagnostic difficulties in small biopsies and cytological specimens

Lukas Bubendorf, Sylvie Lantuejoul, Adrianus J. de Langen, Erik Thunnissen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The pathological and molecular classification of lung cancer has become substantially more complex over the past decade. For diagnostic purposes on small samples, additional stains are frequently required to distinguish between squamous cell carcinoma and adenocarcinoma. Subsequently, for advanced nonsquamous cell nonsmall cell lung carcinoma (NSCLC) patients, predictive analyses on epidermal growth factor receptor, anaplastic lymphoma kinase and ROS1 are required. In NSCLCs negative for these biomarkers, programmed death ligand-1 immunohistochemistry is performed. Small samples (biopsy and cytology) require “tissue” management, which is best achieved by the interaction of all physicians involved.

Original language	English
Article number	170007
Journal	European Respiratory Review
Volume	26
Issue number	144
DOIs	https://doi.org/10.1183/16000617.0007-2017
Publication status	Published - 30 Jun 2017

Access to Document

10.1183/16000617.0007-2017

Link to publication in Scopus

Cite this

Bubendorf, L., Lantuejoul, S., de Langen, A. J., & Thunnissen, E. (2017). Nonsmall cell lung carcinoma: Diagnostic difficulties in small biopsies and cytological specimens. European Respiratory Review, 26(144), [170007]. https://doi.org/10.1183/16000617.0007-2017

@article{16bc2aa420cb48f3baa8999843b0ccf2,

title = "Nonsmall cell lung carcinoma: Diagnostic difficulties in small biopsies and cytological specimens",

abstract = "The pathological and molecular classification of lung cancer has become substantially more complex over the past decade. For diagnostic purposes on small samples, additional stains are frequently required to distinguish between squamous cell carcinoma and adenocarcinoma. Subsequently, for advanced nonsquamous cell nonsmall cell lung carcinoma (NSCLC) patients, predictive analyses on epidermal growth factor receptor, anaplastic lymphoma kinase and ROS1 are required. In NSCLCs negative for these biomarkers, programmed death ligand-1 immunohistochemistry is performed. Small samples (biopsy and cytology) require “tissue” management, which is best achieved by the interaction of all physicians involved.",

author = "Lukas Bubendorf and Sylvie Lantuejoul and {de Langen}, {Adrianus J.} and Erik Thunnissen",

year = "2017",

month = "6",

day = "30",

doi = "10.1183/16000617.0007-2017",

language = "English",

volume = "26",

journal = "European Respiratory Review",

issn = "0905-9180",

publisher = "European Respiratory Society",

number = "144",

}

TY - JOUR

T1 - Nonsmall cell lung carcinoma

T2 - Diagnostic difficulties in small biopsies and cytological specimens

AU - Bubendorf, Lukas

AU - Lantuejoul, Sylvie

AU - de Langen, Adrianus J.

AU - Thunnissen, Erik

PY - 2017/6/30

Y1 - 2017/6/30

N2 - The pathological and molecular classification of lung cancer has become substantially more complex over the past decade. For diagnostic purposes on small samples, additional stains are frequently required to distinguish between squamous cell carcinoma and adenocarcinoma. Subsequently, for advanced nonsquamous cell nonsmall cell lung carcinoma (NSCLC) patients, predictive analyses on epidermal growth factor receptor, anaplastic lymphoma kinase and ROS1 are required. In NSCLCs negative for these biomarkers, programmed death ligand-1 immunohistochemistry is performed. Small samples (biopsy and cytology) require “tissue” management, which is best achieved by the interaction of all physicians involved.

AB - The pathological and molecular classification of lung cancer has become substantially more complex over the past decade. For diagnostic purposes on small samples, additional stains are frequently required to distinguish between squamous cell carcinoma and adenocarcinoma. Subsequently, for advanced nonsquamous cell nonsmall cell lung carcinoma (NSCLC) patients, predictive analyses on epidermal growth factor receptor, anaplastic lymphoma kinase and ROS1 are required. In NSCLCs negative for these biomarkers, programmed death ligand-1 immunohistochemistry is performed. Small samples (biopsy and cytology) require “tissue” management, which is best achieved by the interaction of all physicians involved.

UR - http://www.scopus.com/inward/record.url?scp=85021627705&partnerID=8YFLogxK

U2 - 10.1183/16000617.0007-2017

DO - 10.1183/16000617.0007-2017

M3 - Article

C2 - 28659503

AN - SCOPUS:85021627705

VL - 26

JO - European Respiratory Review

JF - European Respiratory Review

SN - 0905-9180

IS - 144

M1 - 170007

ER -